Kahlil Lawless
Product Marketing Manager, Illumina Inc, Singapore
Title: Frontiers of Next Generation Sequencing in Translational Oncology
Biography
Biography: Kahlil Lawless
Abstract
The steep drop in price and increases in output of Next Generation Sequencing (NGS), as well as the emergence of new methods and studies, are at the forefront in changing our understanding and management of cancer. Kahlil Lawless from Illumina delves into the opportunities and challenges of applying NGS to oncology practice, and highlights recent publications around large-scale initiatives, innovative techniques, and the promise of precision medicine. Next Generation Sequencing (NGS) technologies continue to deliver new insights into cancer biology, and these are being increasingly leveraged to develop new therapies and testing methods to support management of cancer. We review come recent translational studies where Illumina NGS has been used, and evaluate the potential challenges and benefi ts associated with routine adoption of these methods in practice.